The polymorphic inheritance of DIO2 rs225014 may predict body weight variation after Graves’ disease treatment

• Published in: Archives of Endocrinology and Metabolism Vol. 64; no. 6; pp. 787 - 795
• Main Authors: Comarella, Ana Paula, Vilagellin, Danilo, Bufalo, Natassia Elena, Euflauzino, Jessica Ferreira, Teixeira, Elisangela de Souza, Miklos, Ana Beatriz Pinotti Pedro, Santos, Roberto Bernardo dos, Romaldini, João H., Ward, Laura S.
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Endocrinologia e Metabologia 01.11.2021; Brazilian Society of Endocrinology and Metabolism
• Subjects: Body Weight; Case-Control Studies; DIO2 gene; Gene Frequency; Genetic Predisposition to Disease; Graves Disease - genetics; Graves Disease - therapy; Graves’ Disease; Humans; Inheritance Patterns; Iodide Peroxidase - genetics; Iodine Radioisotopes; Iodothyronine Deiodinase Type II; Original; Polymorphism, Single Nucleotide; polymorphisms; DIO2 gene; Graves’ Disease; polymorphisms
• ISSN: 2359-3997; 2359-4292
• DOI: 10.20945/2359-3997000000295

We aimed to investigate the role of polymorphisms rs225014 and rs12885300 in Graves' disease patients, mainly for controlling body weight following treatment. We genotyped 280 GD patients by the time of diagnosis and 297 healthy control individuals using a TaqMan SNP Genotyping technique. We followed up 141 patients for 18.94 ± 6.59 months after treatment. There was no relationship between the investigated polymorphisms with susceptibility to GD and gain or loss of weight after GD treatment. However, the polymorphic inheritance (CC+CT genotype) of rs225014 was associated with a lower body weight variation after GD treatment (4.26 ± 6.25 kg) when compared to wild type TT genotype (6.34 ± 7.26 kg; p = 0.0456 adjusted for the follow-up time). This data was confirmed by a multivariate analysis (p = 0.0138) along with a longer follow-up period (p = 0.0228), older age (p = 0.0306), treatment with radioiodine (p-value = 0.0080) and polymorphic inheritance of rs12885300 (p = 0.0306). We suggest that rs225014 genotyping may have an auxiliary role in predicting the post-treatment weight behavior of GD patients.